November 29, 2016 - By Darrin Black
At average stock price per share of $34.3, Charles Colpo, the Owens & Minor Inc’s SVP – Owens & Minor Europe Ops made a sale of 7,500 shares of Owens & Minor Inc worth approximately $257,475 U.S. Dollars. Charles Colpo presently owns 38,829 shares which are equivalent to around 0.06% of the Virginia-based company’s market cap.
Out of 5 analysts covering Owens & Minor (NYSE:OMI), 0 rate it a “Buy”, 3 “Sell”, while 2 “Hold”. This means 0 are positive. $37 is the highest target while $32 is the lowest. The $35 average target is 2.07% above today’s ($34.29) stock price. Owens & Minor has been the topic of 6 analyst reports since August 25, 2015 according to StockzIntelligence Inc. UBS initiated the stock with “Sell” rating in Thursday, October 6 report. Zacks downgraded Owens & Minor, Inc. (NYSE:OMI) on Tuesday, August 25 to “Hold” rating. The company was downgraded on Monday, November 7 by Bank of America. As per Thursday, April 21, the company rating was downgraded by Robert W. Baird. The stock of Owens & Minor, Inc. (NYSE:OMI) earned “Sector Perform” rating by RBC Capital Markets on Monday, December 7.
Insitutional Activity: The institutional sentiment decreased to 1.22 in 2016 Q2. Its down 0.22, from 1.44 in 2016Q1. The ratio turned negative, as 30 funds sold all Owens & Minor, Inc. shares owned while 72 reduced positions. 33 funds bought stakes while 114 increased positions. They now own 59.84 million shares or 9.03% less from 65.77 million shares in 2016Q1.
The New York-based Alliancebernstein Limited Partnership has invested 0% in Owens & Minor, Inc. (NYSE:OMI). Sandy Spring Bancorp last reported 0.02% of its portfolio in the stock. Mcf Limited has 37 shares for 0% of their US portfolio. Wellington Mgmt Gp Limited Liability Partnership, a Massachusetts-based fund reported 120,975 shares. The Ohio-based Strs Ohio has invested 0.01% in Owens & Minor, Inc. (NYSE:OMI). Convergence Invest Prtnrs Lc accumulated 0.85% or 165,086 shares. First Personal Svcs has invested 0.01% of its portfolio in Owens & Minor, Inc. (NYSE:OMI). Nomura Asset Mgmt Co Ltd has 0% invested in the company for 1,910 shares. Ahl Partners Ltd Liability Partnership has invested 0.28% of its portfolio in Owens & Minor, Inc. (NYSE:OMI). Of Virginia Va reported 8,170 shares or 0.05% of all its holdings. Susquehanna International Group Limited Liability Partnership holds 0% of its portfolio in Owens & Minor, Inc. (NYSE:OMI) for 7,100 shares. Goldman Sachs Grp Inc Inc last reported 584,834 shares in the company. Moreover, Prudential has 0% invested in Owens & Minor, Inc. (NYSE:OMI) for 65,067 shares. Leuthold Gru Ltd Co owns 56,677 shares or 0.22% of their US portfolio. Brown Brothers Harriman & Com has invested 0% of its portfolio in Owens & Minor, Inc. (NYSE:OMI).
Insider Transactions: Since August 5, 2016, the stock had 0 insider purchases, and 2 sales for $365,183 net activity. 2,900 shares with value of $99,499 were sold by DAVIS ERIKA T on Wednesday, August 31. Another trade for 7,500 shares valued at $265,684 was sold by SMITH CRAIG R.
The stock increased 0.32% or $0.11 during the last trading session, hitting $34.29. About 517,886 shares traded hands. Owens & Minor, Inc. (NYSE:OMI) has declined 8.22% since April 26, 2016 and is downtrending. It has underperformed by 13.48% the S&P500.
Owens & Minor, Inc. is a global healthcare services company. The company has a market cap of $2.10 billion. The Firm provides supply chain assistance to the providers of healthcare services and the manufacturers of healthcare products, supplies and devices in the United States and Europe. It has a 18.68 P/E ratio. The Firm operates in two divisions: Domestic and International.
According to Zacks Investment Research, “Owens & Minor, Inc. is one of the nation’s largest distributors of national name brand medical/surgical supplies. With distribution centers located throughout the United States, the company serves hospitals, integrated healthcare systems and group purchasing organizations. In addition to a diverse product offering, Owens & Minor offers innovative services in supply chain management, logistics and technology, helping customers control healthcare costs and improve inventory management.”
Analysts await Owens & Minor, Inc. (NYSE:OMI) to report earnings on February, 13. They expect $0.50 EPS, down 10.71% or $0.06 from last year’s $0.56 per share. OMI’s profit will be $30.62 million for 17.15 P/E if the $0.50 EPS becomes a reality. After $0.51 actual EPS reported by Owens & Minor, Inc. for the previous quarter, Wall Street now forecasts -1.96% negative EPS growth.
More recent Owens & Minor, Inc. (NYSE:OMI) news were published by: Forbes.com which released: “Owens & Minor is Oversold” on August 09, 2016. Also Businesswire.com published the news titled: “Owens & Minor Names Rony C. Kordahi to Serve as Executive Vice President ..” on April 04, 2016. Forbes.com‘s news article titled: “Owens & Minor Becomes Oversold” with publication date: April 20, 2016 was also an interesting one.
Owens & Minor, Inc., incorporated on December 20, 1993, is a global healthcare services company. The Firm provides supply chain assistance to the providers of healthcare services and the manufacturers of healthcare products, supplies and devices in the United States and Europe. The Firm operates in two divisions: Domestic and International. The Domestic segment includes all functions relating to its role as a medical supply logistics firm providing distribution; kitting, including Medical Action Industries Inc. (Medical Action), and logistics services to healthcare providers and manufacturers in the United States. The International segment consists of Movianto Group (Movianto) and ArcRoyal. The Firm serves clients with a service portfolio that covers procurement, inventory management, delivery and sourcing for the healthcare market. With fully developed networks in the United States and Europe, it serves a customer base, ranging from hospitals, integrated healthcare systems, group purchasing organizations and the United States federal government, to manufacturers of life-science and medical devices and supplies, including pharmaceuticals in Europe.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black